Disease · MONDO_0005344

hepatitis B virus infection

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hepatitis B virus infection. Diseases, record MONDO_0005344. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005344

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hepatitis B virus infection; Open Targets
Open Targets ID: MONDO_0005344; Open Targets
Other names: HBV infection, Hepatitis B, Hepatitis B infection, Hepatitis B virus caused hepatitis, Hepatitis B virus hepatitis, hepatitis B, chronic, hepatitis type B, viral Hepatitis B; Open Targets
Disease Ontology: DOID:2043; Disease Ontology
MeSH: D006509; MeSH
NCI Thesaurus: C3097; NCI Thesaurus
Highest stage of its drugs: Approval, for 17 of its 141 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Drugs141

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ENTECAVIR	CHEMBL5314362	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	123	111	110	Drugs and targets
PEGINTERFERON ALFA-2A	CHEMBL1201560	Protein	Approval	DailyMed and EMA Human Drugs	89	87	69	Drugs and targets
TENOFOVIR DISOPROXIL FUMARATE	CHEMBL1486	Small molecule	Approval	ClinicalTrials.gov and PMDA	79	77	75	Drugs and targets
TENOFOVIR ALAFENAMIDE	CHEMBL2107825	Small molecule	Approval	EMA Human Drugs, PMDA and TTD	47	43	43	Drugs and targets
TELBIVUDINE	CHEMBL374731	Small molecule	Approval	TTD	41	39	39	Drugs and targets
LAMIVUDINE	CHEMBL141	Small molecule	Approval	DailyMed, EMA Human Drugs and PMDA	48	36	36	Drugs and targets
ADEFOVIR DIPIVOXIL	CHEMBL922	Small molecule	Approval	ClinicalTrials.gov, DailyMed, PMDA and TTD	41	35	33	Drugs and targets
INTERFERON ALFA-2B	CHEMBL1201558	Protein	Approval	EMA Human Drugs, at withdrawal	20	18	7	Drugs and targets
HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN	CHEMBL4297973	Vaccine component	Approval	EMA Human Drugs and TTD	27	15	14	Drugs and targets
TENOFOVIR DISOPROXIL	CHEMBL1538	Small molecule	Approval	EMA Human Drugs	10	9	9	Drugs and targets

1 to 10 of 141

See all 141 drugs

Targets122

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
IFNAR1	Interferon alpha/beta receptor	5	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Approval	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	5	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Approval	https://conductscience.org/library/genes/3455	Drugs and targets
PDCD1	Programmed cell death protein 1	5	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
KDR	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	3	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	3	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
SLC10A1	Hepatic sodium/bile acid cotransporter	3	Bile acid transporter inhibitor	Phase 2	https://conductscience.org/library/genes/6554	Drugs and targets
BRAF	Serine/threonine-protein kinase B-raf	2	Serine/threonine-protein kinase B-raf inhibitor	Phase 2	https://conductscience.org/library/genes/673	Drugs and targets
CD274	Programmed cell death 1 ligand 1	2	Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets

1 to 10 of 122

See all 122 targets

Trials455

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 17 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00388674	Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection		12,522	2018-07-30	Chronic Hepatitis B	ENTECAVIR	Its record names the disease	ClinicalTrials.gov
NCT01329419	HEPSERA Post Marketing Surveillance		4,393	2011-04-05	Hepatitis B	ADEFOVIR DIPIVOXIL	Its record names the disease	ClinicalTrials.gov
NCT01855997	A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue		1,669	2016-04-08	Hepatitis B, Chronic	PEGINTERFERON ALFA-2A	Its record names the disease	ClinicalTrials.gov
NCT01438424	Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials	Phase 2	1,053	2012-08-23	Hepatitis B Virus, HBV	ENTECAVIR	Its record names the disease	ClinicalTrials.gov
NCT01940471	Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen	Phase 3	875	2017-03-30	HBeAg-positive Chronic Hepatitis B	TENOFOVIR ALAFENAMIDE, TENOFOVIR DISOPROXIL FUMARATE	Its record names the disease	ClinicalTrials.gov
NCT00543725	TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors	Phase 3	680	2011-07-12	HIV Infections, HIV-1	EFAVIRENZ, RILPIVIRINE	Its record names the disease	ClinicalTrials.gov
NCT00536263	PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)	Phase 3	671	2010-12-21	Hepatitis B, Chronic	PEGINTERFERON ALFA-2B	Its record names the disease	ClinicalTrials.gov
NCT00410072	Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B	Phase 3	669	2012-02-03	Hepatitis B, Chronic	ENTECAVIR, TENOFOVIR DISOPROXIL FUMARATE	Its record names the disease	ClinicalTrials.gov
NCT00410202	Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus	Phase 3	629	2012-07-04	Hepatitis B, Chronic	ADEFOVIR, ENTECAVIR	Its record names the disease	ClinicalTrials.gov
NCT00435825	A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).	Phase 4	551	2013-06-25	Hepatitis B, Chronic	PEGINTERFERON ALFA-2A	Its record names the disease	ClinicalTrials.gov

1 to 10 of 455

See all 455 trials

Comparisons in its trials95

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Entecavir (ETV) vs Other Anti-HBV Medication (Non-ETV): Number of Deaths	238 of 6,216	264 of 6,162	12,378	NCT00388674	Trial comparisons
Entecavir (ETV) vs Other Anti-HBV Medication (Non-ETV): Number of Participants With HCC Malignant Neoplasm	240 of 6,216	263 of 6,162	12,378	NCT00388674	Trial comparisons
Entecavir (ETV) vs Other Anti-HBV Medication (Non-ETV): Number of Participants With Liver-related HBV Disease Progression	350 of 6,216	375 of 6,162	12,378	NCT00388674	Trial comparisons
Entecavir (ETV) vs Other Anti-HBV Medication (Non-ETV): Number of Participants With Non-HCC Malignant Neoplasm	95 of 6,216	81 of 6,162	12,378	NCT00388674	Trial comparisons
Entecavir (ETV) vs Other Anti-HBV Medication (Non-ETV): Number of Participants With Adjudicated Overall Malignant Neoplasms	331 of 6,216	337 of 6,162	12,378	NCT00388674	Trial comparisons
Entecavir (ETV) vs Other Anti-HBV Medication (Non-ETV): Number of Participants With Liver-related Death	46 of 6,216	48 of 6,162	12,378	NCT00388674	Trial comparisons
Entecavir (ETV) vs Other Anti-HBV Medication (Non-ETV): serious adverse events	56 of 6,216	50 of 6,162	12,378	NCT00388674	Trial comparisons
TMC278 vs Efavirenz: Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <400 Copies Per mL) at Week 48	300 of 340	286 of 338	678	NCT00543725	Trial comparisons
TMC278 vs Efavirenz: Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <400 Copies Per mL) at Week 96	283 of 340	270 of 338	678	NCT00543725	Trial comparisons
TMC278 vs Efavirenz: serious adverse events	32 of 340	31 of 338	678	NCT00543725	Trial comparisons

1 to 10 of 95

See all 95 comparisons in its trials

Papers from its trials268

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38881506	RESULT	1	PubMed
37882252	RESULT	1	PubMed
35870702	RESULT	1	PubMed
35090390	RESULT	1	PubMed
33465271	RESULT	1	PubMed
33404182	RESULT	1	PubMed
32304611	RESULT	1	PubMed
32282538	RESULT	1	PubMed
32087795	RESULT	1	PubMed
31994737	RESULT	1	PubMed

1 to 10 of 268

See all 268 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005344

GET https://conductscience.org/api/diseases/v1/MONDO_0005344/drugs?page=2

API reference For AI assistants